Clinical trials: Standard Therapy
Acute Heart Failure
Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF
The purpose of the study was to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.
- Trial name
- RELAX-AHF-ASIA (NCT02007720)
- Testing
- Serelaxin, Standard of CareTherapy
- Where
- 132 sites in China, India and 9 more
- Volunteers
- 876 people
- Sponsor
- Novartis Pharmaceuticals
Infections, Gram-Positive Bacterial, Abscess
Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. One of the ways to deal with this problem is to develop new drugs that can control these bacteria.
- Conditions
- Infections, Gram-Positive Bacterial, Abscess, Burns, Cellulitis
- Trial name
- FAST (NCT00061633)
- Testing
- Telavancin, Vancomycin or antistaphylococcal penicillin
- Where
- United States
- Volunteers
- 169 people
- Sponsor
- Cumberland Pharmaceuticals
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
This phase I trial studies how well chemokine modulation therapy and standard chemotherapy given before surgery work in treating patients with early stage triple negative breast cancer.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8
- Trial name
- NCT04081389
- Testing
- Celecoxib, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
TOBACCO USE CESSATION
Comparison of Standard Versus Extended Nicotine Patch Therapy for Smoking Cessation
This randomized double-blind, placebo-controlled will determine the relative efficacy of standard versus extended transdermal nicotine (TN) therapy for smoking cessation.
- Trial name
- NCT00364156
- Testing
- Standard Patch Treatment, 24-weeks of nicotine patch
- Where
- 2 sites in United States
- Volunteers
- 568 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Arthritis, Psoriatic
Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.
This clinical study will test the effects of a drug called apremilast in oligoarticular psoriatic arthritis with less than 5 years of disease duration.
- Trial name
- FOREMOST (NCT03747939)
- Testing
- Apremilast (CC-10004)
- Where
- 114 sites in United States, Austria and 9 more
- Volunteers
- 310 people
- Sponsor
- Amgen
Acute Myeloid Leukemia
Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia
This was an exploratory Phase 2, open label, randomized, multicenter, parallel group study to determine whether there was evidence that the addition of dociparstat (CX-01) at 2 different does levels to standard induction therapy…
- Trial name
- NCT02873338
- Testing
- Dociparstat sodium, Idarubicin, Cytarabine
- Where
- 23 sites in United States
- Volunteers
- 75 people
- Sponsor
- Jazz Pharmaceuticals
Treatment-Resistant Depression
Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)
The main purpose of this study was to evaluate safety and efficacy of a single injection of MIJ821 in addition to standard of care (SoC) pharmacological anti-depressant treatment in participants with treatment-resistant…
- Trial name
- NCT05454410
- Testing
- MIJ821 Subcutaneous Injection 1 mg, MIJ821 Subcutaneous Injection 4 mg, MIJ821 Subcutaneous Injection 10 mg
- Where
- 16 sites in United States, Japan and 2 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2, Acute Coronary Syndrome
Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome
The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in patients with type 2 diabetes mellitus and acute coronary syndrome.
- Trial name
- EXAMINE (NCT00968708)
- Testing
- Alogliptin
- Where
- 908 sites in United States, Argentina and 48 more
- Volunteers
- 5,380 people
- Sponsor
- Takeda
Neoplasms
A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors
A dose escalation study to determine the safety and maximum tolerated dose (MTD) of IMC-3C5 in subjects with advanced solid tumors that are refractory to standard therapy or for which no standard therapy is available.
- Trial name
- NCT01288989
- Testing
- IMC-3C5
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Eli Lilly and Company
Osteo Arthritis Knee
pAF for the Treatment of Osteoarthritis
This is a Phase I/II Randomized Double-Blinded Standard of Care (Corticosteroid) vs. Sterile Amniotic Fluid for Osteoarthritis
- Trial name
- NCT04886960
- Testing
- Amniotic Fluid Injection, Standard of Care
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Utah
Asthma
Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment
This study was a 2-treatment period, randomized, multicenter parallel-group study. The overall purpose of this study was to provide long- term safety data for fevipiprant (QAW039) (Dose 1 and Dose 2), compared with placebo, when…
- Trial name
- NCT03052517
- Testing
- QAW039 150 mg, QAW039 450 mg
- Where
- 347 sites in United States, Argentina and 40 more
- Volunteers
- 2,538 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Foot Ulcer
A Prospective, Randomized, Double-Blind Multicenter Study Comparing CDO Therapy to Standard MWT in the Treatment of DFUs
The purpose of this study was to evaluate the safety and effectiveness of Continuous Diffusion of Oxygen (CDO) therapy for the treatment of Diabetic Foot Ulcers.
- Trial name
- NCT01645891
- Testing
- CDO electrochemical tissue oxygenation system, Moist Wound Therapy
- Where
- 33 sites in United States
- Volunteers
- 146 people
- Sponsor
- Electrochemical Oxygen Concepts, Inc.
Lung Diseases, Interstitial
A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)
This study is open to children and adolescents with interstitial lung disease (ILD) that causes lung fibrosis. This is a study for people who took part in a previous study called InPedILD (study 1199-0337) and for people who are…
- Trial name
- NCT05285982
- Testing
- Nintedanib (Ofev®)
- Where
- 28 sites in United States, Argentina and 15 more
- Volunteers
- 54 people
- Sponsor
- Boehringer Ingelheim
Unspecified Adult Solid Tumor, Protocol Specific
GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as GDC-0449, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00607724
- Testing
- GDC-0449
- Volunteers
- 68 people
- Sponsor
- Genentech, Inc.
Acute Myelogenous Leukemia, Myelodysplastic Syndromes
Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS
The purpose of this trial is to to determine the safety and effectiveness of therapeutic combination - Clofarabine and Cytarabine for the treatment of AML and MDS.
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia
- Trial name
- NCT00334074
- Testing
- Clofarabine and Cytarabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Baylor Research Institute
Uveitis
38 Week Extension Study to CAIN457C2303
A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet's patients with posterior or panuveitis treated with…
- Trial name
- SHIELD (NCT01093846)
- Testing
- AIN457
- Where
- 25 sites in United States, Egypt and 12 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer
Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer
The study is designed to determine whether an accelerated course of hypofractionated radiation therapy with daily image guidance and motion assessment/control will allow more effective treatment of poor performance status…
- Trial name
- NCT01459497
- Testing
- Radiation Therapy, Conventional radiation
- Where
- 7 sites in United States
- Volunteers
- 103 people
- Sponsor
- University of Texas Southwestern Medical Center
Postmenopausal Osteoporosis
Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis
The purpose of this study is to provide 24 months of standard of care data on participants previously enrolled in Study BA058-05-003 (NCT02653417).
- Trial name
- ACTIVExtend (NCT01657162)
- Testing
- Alendronate
- Where
- 25 sites in United States, Argentina and 8 more
- Volunteers
- 1,139 people
- Sponsor
- Radius Health, Inc.
Hodgkin Lymphoma
Proton Therapy for Hodgkin Lymphoma
The purpose of this study is to reduce the risk of radiation related side effects and complications by treating with radiation (protons or photons) that exposes less of normal organs to low dose radiation.
- Trial name
- HL01 (NCT00850200)
- Testing
- Proton Radiation Plan, Conventional Photon Radiation Plan, Intensity Modulated Radiation Plan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Florida
Metastatic Esophageal Squamous Cell Carcinoma
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).
The purpose of this study is to assess the efficacy and safety of pembrolizumab plus lenvatinib plus chemotherapy compared with pembrolizumab plus chemotherapy as first-line intervention in participants with metastatic esophageal…
- Trial name
- NCT04949256
- Testing
- Pembrolizumab, Lenvatinib, Cisplatin
- Where
- 198 sites in United States, Argentina and 23 more
- Volunteers
- 863 people
- Sponsor
- Merck Sharp & Dohme LLC